News
Updated and committed to information
DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS
The authors of this review and meta-analysis of phase III trials evaluated the use of daratumumab for the treatment of newly diagnosed and relapsed/refractory multiple
EFFICACY OF MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER WITH A BRCA MUTATION
Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated efficacy in several tumor types, including advanced ovarian cancer, breast, prostate, and pancreatic cancers. Olaparib is approved
IMPLICATIONS OF TP53 ALLELIC STATE FOR GENOME STABILITY, CLINICAL PRESENTATION AND OUTCOMES IN MYELODYSPLASTIC SYNDROMES
Tumor protein p53 (TP53) is the most frequently mutated gene in cancer. In patients with myelodysplastic síndromes (MDS), TP53 mutations are associated with high-risk disease,
ASSOCIATION OF SPAG5 AND TREATMENT RESPONSE IN PATIENTS WITH ER-POSITIVE BREAST CANCER
Sperm-associated antigen 5 (SPAG5) represents a novel oncogene in estrogen receptor (ER)–positive luminal-B breast cancer. The authors of this study evaluated the association of SPAG5
GENOMIC PROFILING OF SMOLDERING MULTIPLE MYELOMA IDENTIFIES PATIENTS AT A HIGH RISK OF DISEASE PROGRESSION
Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk
NOVARTIS PIQRAY® RECEIVES POSITIVE CHMP OPINION TO TREAT HR+/HER2- ADVANCED BREAST CANCER WITH A PIK3CA MUTATION
Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of Piqray® (alpelisib)
